Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 7989180, 10 pages
https://doi.org/10.1155/2017/7989180
Research Article

Association between Fluorescent Advanced Glycation End-Products and Vascular Complications in Type 2 Diabetic Patients

1Université de La Réunion, INSERM, UMR 1188 Diabète Athérothrombose Thérapies Réunion Océan Indien (DéTROI), Saint-Denis de La Réunion, France
2Centre Hospitalier Gabriel Martin, Saint-Paul, France
3Centre Hospitalier Universitaire de La Réunion, Saint Denis, France

Correspondence should be addressed to Philippe Rondeau; rf.noinuer-vinu@lihpor and Emmanuel Bourdon; rf.noinuer-vinu@nodruob.leunamme

Received 22 May 2017; Revised 11 August 2017; Accepted 10 September 2017; Published 6 December 2017

Academic Editor: Kamel Mohammedi

Copyright © 2017 Alexis Guerin-Dubourg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Ndong, “Caractéristiques, risque vasculaire, complications et qualité des soins des personnes diabétiques dans les départements d'outre-mer et comparaison à la métropole : Entred 2007-2010,” Bull Epidemiol Hebd, vol. 42-43, pp. 432–436, 2010. View at Google Scholar
  2. M. Laakso, “Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the kelly west award lecture 2008,” Diabetes Care, vol. 33, no. 2, pp. 442–449, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Favier, I. Jaussent, N. Le Moullec et al., “Prevalence of Type 2 diabetes and central adiposity in La Réunion Island, the REDIA study,” Diabetes Research and Clinical Practice, vol. 67, no. 3, pp. 234–242, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. S. P. Wolff, Z. Y. Jiang, and J. V. Hunt, “Protein glycation and oxidative stress in diabetes mellitus and ageing,” Free Radical Biology & Medicine, vol. 10, no. 5, pp. 339–352, 1991. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Houstis, E. D. Rosen, and E. S. Lander, “Reactive oxygen species have a causal role in multiple forms of insulin resistance,” Nature, vol. 440, no. 7086, pp. 944–948, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Rondeau and E. Bourdon, “The glycation of albumin: structural and functional impacts,” Biochimie, vol. 93, no. 4, pp. 645–658, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Baraka-Vidot, A. Guerin-Dubourg, E. Bourdon, and P. Rondeau, “Impaired drug-binding capacities of in vitro and in vivo glycated albumin,” Biochimie, vol. 94, no. 9, pp. 1960–1967, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Baraka-Vidot, A. Guerin-Dubourg, F. Dubois, B. Payet, E. Bourdon, and P. Rondeau, “New insights into deleterious impacts of in vivo glycation on albumin antioxidant activities,” Biochimica et Biophysica Acta, vol. 1830, no. 6, pp. 3532–3541, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Guerin-Dubourg, A. Catan, E. Bourdon, and P. Rondeau, “Structural modifications of human albumin in diabetes,” Diabetes and Metabolism, vol. 38, no. 2, pp. 171–178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. N. C. Chilelli, S. Burlina, and A. Lapolla, “AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a “glycoxidation-centric” point of view,” Nutrition, Metabolism & Cardiovascular Diseases, vol. 23, no. 10, pp. 913–919, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Pitocco, M. Tesauro, R. Alessandro, G. Ghirlanda, and C. Cardillo, “Oxidative stress in diabetes: implications for vascular and other complications,” International Journal of Molecular Sciences, vol. 14, no. 11, pp. 21525–21550, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Bar-Or, E. Lau, and J. V. Winkler, “A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report,” Journal of Emergency Medicine, vol. 19, no. 4, pp. 311–315, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Bar-Or, L. T. Rael, R. Bar-Or et al., “The cobalt-albumin binding assay: insights into its mode of action,” Clinica Chimica Acta, vol. 387, no. 1-2, pp. 120–127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Roy and J. C. Kaski, “Ischemia-modified albumin: the importance of oxidative stress,” Journal of the American College of Cardiology, vol. 49, no. 24, pp. 2375-2376, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Ashfaq, J. L. Abramson, D. P. Jones et al., “The relationship between plasma levels of oxidized and reduced thiols and early atherosclerosis in healthy adults,” Journal of the American College of Cardiology, vol. 47, no. 5, pp. 1005–1011, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. R. E. Stauber, W. Spindelboeck, J. Haas et al., “Human nonmercaptalbumin-2: a novel prognostic marker in chronic liver failure,” Therapeutic Apheresis and Dialysis, vol. 18, no. 1, pp. 74–78, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Zagorchev, C. E. Seal, I. Kranner, and M. Odjakova, “Redox state of low-molecular-weight thiols and disulphides during somatic embryogenesis of salt-treated suspension cultures of Dactylis glomerata L.,” Free Radical Research, vol. 46, no. 5, pp. 656–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. D. M. Muoio and C. B. Newgard, “Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes,” Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 193–205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. P. J. Thornalley and N. Rabbani, “Detection of oxidized and glycated proteins in clinical samples using mass spectrometry - a user's perspective,” Biochimica et Biophysica Acta - General Subjects, vol. 1840, no. 2, pp. 818–829, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Ho, K. Karimi Galougahi, C. C. Liu, R. Bhindi, and G. A. Figtree, “Biological markers of oxidative stress: applications to cardiovascular research and practice,” Redox Biology, vol. 1, no. 1, pp. 483–491, 2013. View at Publisher · View at Google Scholar
  21. X. Debussche, F. Collin, A. Fianu et al., “Structured self-management education maintained over two years in insufficiently controlled type 2 diabetes patients: the ERMIES randomised trial in reunion island,” Cardiovascular Diabetology, vol. 11, article 91, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. G. L. Ellman, “Tissue sulfhydryl groups,” Archives of Biochemistry and Biophysics, vol. 82, no. 1, pp. 70–77, 1959. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Chesne, P. Rondeau, S. Armenta, and E. Bourdon, “Effects of oxidative modifications induced by the glycation of bovine serum albumin on its structure and on cultured adipose cells,” Biochimie, vol. 88, no. 10, pp. 1467–1477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Lee, J.-E. Eom, K.-H. Jeon et al., “Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay,” Journal of Pharmaceutical and Biomedical Analysis, vol. 91, pp. 17–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Baraka-Vidot, C. Planesse, O. Meilhac et al., “Glycation alters ligand binding, enzymatic, and pharmacological properties of human albumin,” Biochemistry, vol. 54, no. 19, pp. 3051–3062, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Brownlee, “The pathological implications of protein glycation,” Clin Invest Med, vol. 18, pp. 275–81, 1995. View at Google Scholar
  27. S. M. Son, “Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes,” Diabetes and Metabolism Journal, vol. 36, no. 3, pp. 190–198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. T. J. Lyons, “Glycation and oxidation: a role in the pathogenesis of atherosclerosis,” The American Journal of Cardiology, vol. 71, no. 6, pp. B26–B31, 1993. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Kaefer, S. J. Piva, J. A. M. de Carvalho et al., “Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus,” Clinical Biochemistry, vol. 43, no. 4-5, pp. 450–454, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. K. Sinha, D. C. Gaze, J. R. Tippins, P. O. Collinson, and J. C. Kaski, “Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention,” Circulation, vol. 107, no. 19, pp. 2403–2405, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. M. C. Thomas, M. Woodward, B. Neal et al., “Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes,” Diabetes Care, vol. 38, no. 10, pp. 1891–1897, 2015. View at Publisher · View at Google Scholar
  32. M. Brownlee, A. Cerami, and H. Vlassara, “Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease,” Diabetes/Metabolism Reviews, vol. 4, no. 5, pp. 437–451, 1988. View at Publisher · View at Google Scholar · View at Scopus
  33. M. J. C. Kent, N. D. Light, and A. J. Bailey, “Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro,” Biochemical Journal, vol. 225, no. 3, pp. 745–752, 1985. View at Publisher · View at Google Scholar · View at Scopus
  34. D. R. Sell, A. Lapolla, P. Odetti, J. Fogarty, and V. M. Monnier, “Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM,” Diabetes, vol. 41, no. 10, pp. 1286–1292, 1992. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Hegab, S. Gibbons, L. Neyses, and M. A. Mamas, “Role of advanced glycation end products in cardiovascular disease,” World Journal of Cardiology, vol. 4, no. 4, pp. 90–102, 2012. View at Publisher · View at Google Scholar
  36. N. M. J. Hanssen, L. Engelen, I. Ferreira et al., “Plasma levels of advanced glycation endproducts Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 8, pp. E1369–E1373, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Busch, S. Franke, G. Wolf et al., “The advanced glycation end product Nε-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension,” American Journal of Kidney Diseases, vol. 48, no. 4, pp. 571–579, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Pia de la Maza, F. Garrido, N. Escalante et al., “Fluorescent advanced glycation end-products (ages) detected by spectro-photofluorimetry, as a screening tool to detect diabetic microvascular complications,” Journal of Diabetes Mellitus, vol. 02, no. 02, pp. 221–226, 2012. View at Publisher · View at Google Scholar
  39. T. J. Sims, L. M. Rasmussen, H. Oxlund, and A. J. Bailey, “The role of glycation cross-links in diabetic vascular stiffening,” Diabetologia, vol. 39, no. 8, pp. 946–951, 1996. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Yoshida, K.-I. Okumura, and Y. Aso, “High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes,” Metabolism: Clinical and Experimental, vol. 54, no. 3, pp. 345–350, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Zhou, Z. Yu, H. Jia et al., “Association of serum pentosidine with arterial stiffness in hemodialysis patients,” Artificial Organs, vol. 34, no. 3, pp. 193–199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Raposeiras-Roubín, B. K. Rodiño-Janeiro, B. Paradela-Dobarro et al., “Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome,” PLoS ONE, vol. 8, no. 9, Article ID e74302, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. S. G. Ma, C. L. Wei, B. Hong, and W. N. Yu, “Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease,” Clinics (Sao Paulo), vol. 66, pp. 1677–80, 2011. View at Google Scholar
  44. N. Katakami, H. Kaneto, and I. Shimomura, “Carotid ultrasonography: a potent tool for better clinical practice in diagnosis of atherosclerosis in diabetic patients,” Journal of Diabetes Investigation, vol. 5, no. 1, pp. 3–13, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Gunduz, S. Turedi, A. Mentese et al., “Ischemia-modified albumin levels in cerebrovascular accidents,” American Journal of Emergency Medicine, vol. 26, no. 8, pp. 874–878, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Zhong, N. Wang, H. Xu, X. Hou, P. Xu, and Z. Zhou, “Ischemia-modified albumin in stable coronary atherosclerotic heart disease: clinical diagnosis and risk stratification,” Coronary Artery Disease, vol. 23, no. 8, pp. 538–541, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Liao and J. Farmer, “Arterial stiffness as a risk factor for coronary artery disease.,” Current atherosclerosis reports, vol. 16, no. 2, p. 387, 2014. View at Publisher · View at Google Scholar · View at Scopus